Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004;64(24):8867-75. doi:10.1158/0008-5472.CAN-04-2938
Tyekucheva S, Martin NE, Stack EC, et al. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015;17(4):374-81. doi:10.1016/j.jmoldx.2015.02.002
Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10(6):594-601. doi:10.1038/nm1052
Cacciatore S, Loda M. Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci. 2015;1346(1):57-62. doi:10.1111/nyas.12775
Rohland N, Reich D. Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture. Genome Res. 2012;22(5):939-46. doi:10.1101/gr.128124.111
Gan W, Dai X, Lunardi A, et al. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell. 2015;59(6):917-30. doi:10.1016/j.molcel.2015.07.026
Benassi B, Flavin R, Marchionni L, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. doi:10.1158/2159-8290.CD-11-0219
Spisák S, Lawrenson K, Fu Y, et al. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med. 2015;21(11):1357-63. doi:10.1038/nm.3975
Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9. doi:10.1038/ng.2279
Rand KA, Rohland N, Tandon A, et al. Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Hum Mol Genet. 2016;25(2):371-81. doi:10.1093/hmg/ddv462